Latest Demethylating agent Stories
Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer.
The Moffitt Cancer Center announced today that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug's label.
The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial.
Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS).
MethylGene has initiated a Phase II clinical trial evaluating MGCD0103, an isoform-selective histone deacetylase inhibitor product candidate, in combination with Vidaza, a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia.
MONTREAL, QUEBEC--(Marketwire - June 25, 2008) - MethylGene Inc.
BOULDER, Colo., and KYOTO, Japan, Nov. 21 /PRNewswire-FirstCall/ -- Pharmion Corporation and Nippon Shinyaku Co., Ltd today announced the completion of an exclusive license agreement for development and commercialization rights to Vidaza (azacitidine for injectable suspension) in Japan.
- The governor of a province or people.